Nontuberculous Mycobacteria (NTM) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Nontuberculous Mycobacteria Market Overview
The Nontuberculous mycobacteria market size in the US, the UK, and Japan was $8.59 billion in 2021 and is expected to achieve a CAGR of more than 2% during 2021-2031. The NTM market will grow as the diagnosed prevalent cases of nontuberculous mycobacteria (NTM) infections are expected to increase in the US, the UK, and Japan between 2021 and 2031.
The NTM market research report provides an analysis of the key dynamics of the NTM drugs market. The report also offers insights into the key industry drivers and challenges. It also covers deals and R&D strategies in detail to highlight potential business opportunities.
To gain more information on the NTM market forecast, download a free report sample
NTM Market Drivers
Many pipeline agents are first-in-class therapies. This will drive the growth of the NTM market during the forecast period. Improving recognition and diagnosis of NTM in the healthcare community and the launch of improved and timely diagnostic tools that identify NTM species will further drive the growth of the market in focus in the coming years.
NTM Market Unmet Needs and Opportunities
There is a lack of late-stage pipeline products in development for antibiotics across the nontuberculous mycobacteria market. However, as the prevalence of NTM is increasing, drug companies are running campaigns to promote awareness and understanding of NTM among health care providers, patients, and the general public. This could lead to improved diagnosis and treatment rates, which will drive investment in the NTM market for R&D.
NTM Market Segmentation by Class of Drugs
The key classes of drugs in the NTM market are oral antibiotics, IV antibiotics, anti nausea, and nebulized antibiotics. In 2021, oral antibiotics had the largest market share in terms of value.
NTM Market Analysis, by Class of Drugs
For more insights on classes of drugs in the NTM market, download a free report sample
NTM Market - Competitive Landscape
Some of the leading players in the NTM market are Insmed, RedHill Biopharma Ltd, Novartis AG, Paratek Pharmaceuticals Inc, Janssen, RevImmune, and Nobelpharma Co Ltd. Most of the companies had products in phase III of the development stage.
NTM Market Report Overview
| Market Size (in 2021 in The US, The UK, and Japan) | $8.59 billion |
| CAGR (2021 – 2031) | >2% |
| Key Class of Drugs | Oral Antibiotics, IV Antibiotics, Anti Nausea, and Nebulized Antibiotics |
| Leading Players | Insmed, RedHill Biopharma Ltd, Novartis AG, Paratek Pharmaceuticals Inc, Janssen, RevImmune, and Nobelpharma Co Ltd |
Scope
This report provides
- Overview of NTM its pathogenicity, manifestations, and types of infection.
- Epidemiology that looks into the diagnosed incident and prevalent cases of NTM by sex and by 3MM.
- Overview of diagnostics and treatment, treatment profiles of combination therapy for different NTM strains.
- Quotes from three key opinion leaders (KOLs) from the 3MM.
- Key topics covered for NTM drugs in the 3MM include trends, pipeline and market analysis, opportunities, challenges, and unmet needs.
- Pipeline assessment: emerging novel trends under development, and analysis of the most promising late-stage NTM pipeline drugs in clinical development.
- Analysis of the key dynamics of the NTM drugs market. Insightful review of the key industry drivers and challenges.
- Deals and R&D strategies covered in detail to highlight potential business opportunities.
Reasons to Buy
The report will help to understand:
- What impact will late-stage pipeline agents have on the market? Which class of NTM drugs will have the highest peak sales, and why?
- What country in the 3MM will experience the most growth, and why?
- What are the current unmet needs and which pipeline drugs or strategies are positioned to counter these unmet needs? What are the opportunities for R&D in the NTM space?
- How is the field of NTM therapies going to move forward?
- What is the current and future outlook for NTM therapeutics according to KOLs?
Novartis AG
Insmed Inc
Nobelpharma Co Ltd
Paratek Pharmaceuticals Inc
Revimmune LLC
RedHill Biopharma Ltd
RevImmune SAS
Insmed Ltd
Table of Contents
Frequently asked questions
-
What was the NTM market size in the US, the UK, and Japan in 2021?
The NTM market was valued at $8.59 billion in 2021 in the US, the UK, and Japan.
-
What is the NTM market growth rate?
The NTM market is expected to achieve a CAGR of more than 2% during 2021-2031.
-
What are the key classes of drugs in the NTM market?
The key classes of drugs in the NTM market are oral antibiotics, IV antibiotics, anti nausea, and nebulized antibiotics.
-
Who are the leading players in the NTM market?
Some of the leading players in the NTM market are Insmed, RedHill Biopharma Ltd, Novartis AG, Paratek Pharmaceuticals Inc, Janssen, RevImmune, and Nobelpharma Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Infectious Disease reports
